Hospitals and clinics told regulators that switching to rebates in the 340B drug discount program would impose costs that would outweigh the program’s benefits.
The 340B Drug Pricing Program must be reformed to better patient health and disincentivize institutional profit-seeking ...
Regarding the April 20 editorial “Corporate welfare for hospitals is raising health care costs”: There are many commonsense, ...
The AHA responds to the Health Resources and Services Administration’s (HRSA) Request for Information regarding a potential 340B Rebate Model Pilot Program.
B makes it possible for community health organizations to stretch scarce resources and reinvest savings where they belong — ...
Hospital and pharma groups have sharpened their spears for the rematch on 340B rebates. | The administration's second stab ...
In February 2026, the Department of Justice filed amicus briefs supporting pharmaceutical manufacturers, asserting that Rhode ...
VytlAIQ enables health care providers to optimize 340B performance, reduce referral leakage, scale pharmacy operations, and improve patient outcomes and experience through AI-enabled pharmacy care.
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program ...
The federal program was created in 1992 to help hospitals and clinics in poor communities. In recent weeks, it has become the ...
NuvemRx, a tech-enabled pharmacy solutions company for community health providers, today announced the launch of Mission ...
AHA urges HRSA to axe 340B model that would cost hospitals over $1 billion annually and increase administrative burdens.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results